Market segments covered by this report include tissue engineering and cell transplantation products for the treatment of neurologic diseases/disorders including Alzheimer's disease, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease, peripheral nerve regeneration, spinal cord injury, and stroke. A variety of tissue engineering approaches show promise for treating diseases and disorders of the central nervous system, and many companies are developing product candidates for the U.S. market based on several technologies including gene therapy, growth factors, monoclonal antibodies, nerve grafting, and stem cells.
In addition, this report includes an overview of some of the most prevalent neurologic disorders and diseases in the U.S. as well as an analysis of emerging competitors and products/technologies that currently are under development.
This Medtech Insight report is the third in a series of reports covering U.S. tissue engineering markets. Upcoming reports in this series will provide analyses of U.S. markets for tissue-engineered products for organ regeneration, skin replacement, and urology applications.
EXECUTIVE SUMMARY i. The Nervous System ii. Neurologic and Other Diseases/Disorders a. Alzheimer's Disease b. Amyotrophic Lateral Sclerosis c. Epilepsy d. Multiple Sclerosis e. Parkinson's Diseases f. Stroke iii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iv. Current and Emerging Markets for Neurologic Tissue Engineering and Cell Transplantation Products a. Gene Therapy b. Growth Factors c. Nerve Grafting d. Stem Cell-Based Therapies e. Other Tissue Engineering Technologies f. Market Analysis v. Methodology Exhibit ES-1: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019 1. OVERVIEW OF THE NERVOUS SYSTEM AND SELECTED NEUROLOGIC DISEASES/DISORDERS 1.1 The Nervous System 1.1.1 Sacral Nerves 1.1.2 Vagus Nerves 1.1.3 Neurons 1.1.4 The Brain 1.1.5 The Spine 1.2 Neurologic and Other Diseases/Disorders 1.2.1 Alzheimer's Disease 188.8.131.52 Etiology 184.108.40.206 Epidemiology 1.2.2 Amyotrophic Lateral Sclerosis 220.127.116.11 Etiology 18.104.22.168 Epidemiology 1.2.3 Epilepsy 22.214.171.124 Etiology 126.96.36.199 Epidemiology 1.2.4 Multiple Sclerosis 188.8.131.52 Etiology 184.108.40.206 Epidemiology 1.2.5 Parkinson's Disease 220.127.116.11 Etiology 18.104.22.168 Epidemiology 1.2.6 Stroke 22.214.171.124 Etiology 126.96.36.199 Epidemiology Exhibit 1-1: United States Population, by Age Group, Selected Years, 2000-2050 Exhibit 1-2: The Sacral Nervous System Exhibit 1-3: The Vagus Nerve Exhibit 1-4: Anatomy of the Brain Exhibit 1-5: Anatomy of a Spinal Segment Exhibit 1-6: Alzheimer's Disease, Facts and Figures Exhibit 1-7: Amyotrophic Lateral Sclerosis, Facts and Figures Exhibit 1-8: Epilepsy, Facts and Figures Exhibit 1-9: Multiple Sclerosis, Facts and Figures Exhibit 1-10: Parkinson's Disease, Facts and Figures Exhibit 1-11: Stroke, Facts and Figures 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 188.8.131.52 Collagen 184.108.40.206 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 220.127.116.11 Deoxyribonucleic Acid Transfection Vectors 18.104.22.168 Genetically Manipulated Cells 22.214.171.124 Three-Dimensional Polymer Technology 126.96.36.199 Transgenics 188.8.131.52 Fibroblasts 184.108.40.206 Immortalized Neural Stem Cells 220.127.116.11 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 18.104.22.168 Flatbed Perfusion Systems 22.214.171.124 Hollow Fiber Bioreactor Systems 126.96.36.199 Cell Suspension Systems 188.8.131.52 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. CURRENT AND EMERGING MARKETS FOR NEUROLOGIC TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS 3.1 Gene Therapy 3.1.1 Ceregene 3.1.2 Genzyme 3.1.3 Isis Pharmaceuticals 3.2 Growth Factors 3.2.1 Acorda Therapeutics 3.2.2 Alseres Pharmaceuticals 3.2.3 NeuroNova in collaboration with Medtronic 3.2.4 The Parkinson Study Group 3.3 Nerve Grafting 3.3.1 AxoGen 3.3.2 Integra LifeSciences 3.4 Peptides 3.4.1 CellMed/Biocompatibles International 3.5 Remyelinating Monoclonal Antibodies 3.5.1 Acorda Therapeutics 3.6 Stem Cell-Based Therapies 3.6.1 Human Adult Stem Cells 184.108.40.206 BrainStorm Cell Therapeutics 220.127.116.11 NeuroNova 18.104.22.168 ReNeuron 3.6.2 Human Embryonic Stem Cells 22.214.171.124 Geron 3.6.3 Fetal Neural Stem Cells 126.96.36.199 Neuralstem 188.8.131.52 StemCells 3.6.4 Fetal Porcine Cells 3.6.5 Nasal Cavity-Derived Stem Cells 3.6.6 Skin-Derived Stem Cells 3.7 Retinal Pigmented Epithelial Cell Transplants 3.7.1 Titan Pharmaceuticals in collaboration with Bayer 3.8 Market Analysis 3.8.1 Market Drivers 3.8.2 Market Limiters 3.9 Competitive Analysis Exhibit 3-1: 2010, Selected Tissue-Engineered/Regeneration Products for Neurology Applications Exhibit 3-2: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-3: Technologies for Neurologic Tissue Engineering, by Indication, 2009 and 2019 Exhibit 3-4: Technologies for Tissue Engineering and Cell Transplantation, Product Introduction Forecast, by Indication, 2014 and 2019 4. COMPANY PROFILES 4.1 Acorda Therapeutics, Inc. 4.2 AxoGen, Inc. 4.3 Ceregene, Inc. 4.4 Genzyme Corporation 4.5 Geron Corporation 4.6 Integra LifeSciences Corporation 4.7 Isis Pharmaceuticals, Inc. 4.8 Neuralstem, Inc. 4.9 NeuroNova AB 4.10 ReNeuron Group PLC APPENDIX: COMPANY LISTING